Who
Jennifer A. Fox
Director
Company insider
Files Form 4 as: Director, Apogee Therapeutics; Officer, Zenas BioPharma; Director, ProKidney; Chief Financial Officer, Nuvation Bio.
In numbers
- Trades disclosed
- 32
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 10 Feb 2021
- Last trade
- 3 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | —34,824 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,370 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,461 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,370 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,461 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,657 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,657 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | —34,824 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,657 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,657 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 5 Feb 2026filed 17 Jun 2026 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Code A | $21K1,592 at $13.35 | filing |
| 5 Feb 2026filed 17 Jun 2026 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Code A | $21K1,592 at $13.35 | filing |
| 17 Jun 2025filed 20 Jun 2025 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,461 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,862 at $0.00 | filing |
| 16 Dec 2024filed 18 Dec 2024 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,125 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.